Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
CLEVIPREX—a dihydropyridine calcium channel blocker—can provide blood pressure (BP) reduction in the perioperative setting and in case of acute severe hypertension. CLEVIPREX is a ready-to-use option and has a ~1-minute half-life.1
Titratable Control of blood pressure reduction with CLEVIPREX® (clevidipine)
BP reduction in a range of patients and clinical settings1-5
Proven efficacy in:
- Perioperative hypertension
- Acute severe hypertension
- Intracerebral hemorrhage (ICH)
Established safety profile in multiple clinical trials2,3,6
CLEVIPREX demonstrated safety vs:
- Nicardipine in postoperative hypertension
- Sodium nitroprusside and nitroglycerin in perioperative hypertension
- Placebo in perioperative hypertension
Rapidly lowers arterial BP with fast onset and offset1
- Titratable, fast onset of action (within 2 minutes of initiation)
- ~1-minute half-life
- Metabolized independent of renal or hepatic function
Non–weight-based dosing1
CLEVIPREX dosing is also:
- A low infusion volume1
- Available as ready-to-use 50- and 100-mL vials1
Low-volume dosing option1
Excessive fluid intake may lead to adverse outcomes in critically ill patients7,8:
- Consider the results of the ECLIPSE trials
- See how infusion volumes varied between hypertensive agents in the postoperative setting
CLEVIPREX has not been studied or proven to impact fluid overload.
AIS Guideline Information
Cleviprex is a recommended option in the AIS guidelines since 2018.
ICH Guideline Information
AHA/ASA guidelines emphasize smooth, sustained blood pressure control for ICH.
Access CLEVIPREX Resources
Watch KOL videos or download guideline summaries, dosing cards and more.